Henry Ryan A, Kuo Yin-Ming, Bhattacharjee Vikram, Yen Timothy J, Andrews Andrew J
Department of Cancer Biology, 333 Cottman Avenue, Fox Chase Cancer Center , Philadelphia, Pennsylvania United States.
ACS Chem Biol. 2015 Jan 16;10(1):146-56. doi: 10.1021/cb500726b. Epub 2014 Nov 6.
Determining how histone acetylation is regulated is vital for treating the many diseases associated with its misregulation, including heart disease, neurological disorders, and cancer. We have previously reported that acetyl-CoA levels alter p300 histone acetylation in a site-specific manner in vitro. Here, we further investigate how changing acetyl-CoA concentrations alter the histone acetylation pattern by altering p300 specificity. Interestingly, these changes are not a simple global change in acetylation, but rather site specific changes, whereby acetylation at some sites increase while others decrease. We also demonstrate how the p300 inhibitor C646 can pharmacologically alter p300 histone acetylation patterns in vitro and in cells. This study provides insight into the mechanisms regulating p300 residue specificity, a potential means for altering p300 dependent histone acetylation, and an investigation into altering histone acetylation patterns in cells.
确定组蛋白乙酰化是如何被调控的,对于治疗许多与其调控异常相关的疾病至关重要,这些疾病包括心脏病、神经紊乱和癌症。我们之前曾报道,在体外,乙酰辅酶A水平以位点特异性的方式改变p300组蛋白乙酰化。在此,我们进一步研究改变乙酰辅酶A浓度如何通过改变p300特异性来改变组蛋白乙酰化模式。有趣的是,这些变化并非简单的乙酰化全局变化,而是位点特异性变化,即某些位点的乙酰化增加而其他位点的乙酰化减少。我们还展示了p300抑制剂C646如何在体外和细胞中通过药理学方式改变p300组蛋白乙酰化模式。这项研究深入了解了调控p300残基特异性的机制、一种改变p300依赖性组蛋白乙酰化的潜在方法以及对改变细胞中组蛋白乙酰化模式的研究。